TW281675B - - Google Patents
Info
- Publication number
- TW281675B TW281675B TW083103768A TW83103768A TW281675B TW 281675 B TW281675 B TW 281675B TW 083103768 A TW083103768 A TW 083103768A TW 83103768 A TW83103768 A TW 83103768A TW 281675 B TW281675 B TW 281675B
- Authority
- TW
- Taiwan
- Prior art keywords
- antagonism
- compounds
- present
- tachykinin
- neurokinin
- Prior art date
Links
- 230000008485 antagonism Effects 0.000 abstract 3
- 102000003141 Tachykinin Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108060008037 tachykinin Proteins 0.000 abstract 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 101800000399 Neurokinin A Proteins 0.000 abstract 1
- 102400000097 Neurokinin A Human genes 0.000 abstract 1
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 abstract 1
- 102100024304 Protachykinin-1 Human genes 0.000 abstract 1
- 101800003906 Substance P Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5860693A | 1993-05-06 | 1993-05-06 | |
| US21848394A | 1994-03-28 | 1994-03-28 | |
| US22537194A | 1994-04-19 | 1994-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW281675B true TW281675B (enExample) | 1996-07-21 |
Family
ID=27369482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW083103768A TW281675B (enExample) | 1993-05-06 | 1994-04-26 |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0696280B1 (enExample) |
| JP (1) | JP3424174B2 (enExample) |
| CN (1) | CN1081635C (enExample) |
| AT (1) | ATE158580T1 (enExample) |
| AU (1) | AU678023B2 (enExample) |
| CA (1) | CA2160462C (enExample) |
| DE (1) | DE69405862T2 (enExample) |
| DK (1) | DK0696280T3 (enExample) |
| ES (1) | ES2110761T3 (enExample) |
| FI (1) | FI113047B (enExample) |
| GR (1) | GR3025475T3 (enExample) |
| HU (1) | HU224496B1 (enExample) |
| IL (1) | IL109496A (enExample) |
| MX (1) | MX9403386A (enExample) |
| NO (1) | NO309144B1 (enExample) |
| NZ (1) | NZ267209A (enExample) |
| TW (1) | TW281675B (enExample) |
| WO (1) | WO1994026735A1 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2717802B1 (fr) * | 1994-03-25 | 1996-06-21 | Sanofi Sa | Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
| WO1996006094A1 (en) | 1994-08-25 | 1996-02-29 | Merrell Pharmaceuticals Inc. | Novel substituted piperidines useful for the treatment of allergic diseases |
| EP0714891A1 (en) * | 1994-11-22 | 1996-06-05 | Eli Lilly And Company | Heterocyclic tachykinin receptor antagonists |
| FR2728169A1 (fr) * | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales |
| FR2728165A1 (fr) * | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene |
| FR2729954B1 (fr) * | 1995-01-30 | 1997-08-01 | Sanofi Sa | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| ES2164235T3 (es) * | 1995-03-15 | 2002-02-16 | Aventis Pharma Inc | Derivados de piperazinona sustituidos por un heterociclo que actuan como antagonistas del receptor de taquiquinina. |
| NZ306022A (en) * | 1995-04-13 | 1998-09-24 | Hoechst Marion Roussel Inc | Phenyl, naphthyl or indolyl substituted piperazine derivatives and medicaments |
| US5661163A (en) * | 1995-06-07 | 1997-08-26 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| FR2738245B1 (fr) * | 1995-08-28 | 1997-11-21 | Sanofi Sa | Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant |
| FR2738819B1 (fr) * | 1995-09-14 | 1997-12-05 | Sanofi Sa | Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant |
| ATE182788T1 (de) | 1995-10-10 | 1999-08-15 | Pfizer | Nk-1 rezeptor antagonisten in neurogener entzündung in gen-therapie |
| US6211199B1 (en) | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
| HU224225B1 (hu) * | 1995-12-01 | 2005-06-28 | Sankyo Co. Ltd. | Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására |
| US6423704B2 (en) | 1995-12-20 | 2002-07-23 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases |
| ES2177827T3 (es) * | 1995-12-20 | 2002-12-16 | Aventis Pharma Inc | 4-(1h-bencimidazol-2-il)(1,4)diazepanes utiles para el tratamiento de enfermedades alergicas. |
| US6194406B1 (en) | 1995-12-20 | 2001-02-27 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease |
| GB9600235D0 (en) | 1996-01-05 | 1996-03-06 | Pfizer Ltd | Therapeutic agents |
| US5922737A (en) * | 1996-02-21 | 1999-07-13 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases |
| US5998439A (en) | 1996-02-21 | 1999-12-07 | Hoescht Marion Roussel, Inc. | Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases |
| US5932571A (en) * | 1996-02-21 | 1999-08-03 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases |
| US5977139A (en) * | 1996-12-15 | 1999-11-02 | Hoechst Marion Roussel, Inc. | Carboxysubstituted cyclic carboxamide derivatives |
| US5861417A (en) * | 1996-12-19 | 1999-01-19 | Hoechst Marion Roussel, Inc. | Heterocyclic substituted pyrrolidine amide derivatives |
| KR100468552B1 (ko) * | 1996-12-19 | 2005-01-29 | 아벤티스 파마슈티칼스 인크. | 카르복시 치환된 신규 시클릭 카르복스아미드 유도체 |
| CA2275527C (en) * | 1996-12-19 | 2003-09-23 | Hoechst Marion Roussel, Inc. | Novel heterocyclic substituted pyrrolidine amide derivatives |
| CZ296599B6 (cs) | 1997-05-30 | 2006-04-12 | Sankyo Company Limited | Hydrochlorid nebo fumarát 1-{2-[(2R)-(3,4-dichlorfenyl)-4-(3,4,5-trimethoxybenzoyl)morfolin-2-yl]ethyl}spiro[benzo(c)thiofen-1(3H),4'-piperidin]-(2S)-oxidu a prostredek ho obsahující |
| ID29137A (id) * | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
| CN1414953A (zh) | 1999-11-03 | 2003-04-30 | 阿尔巴尼分子研究公司 | 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和5－羟色胺重摄取的用途 |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| BR0112350A (pt) | 2000-07-11 | 2003-06-24 | Albany Molecular Res Inc | Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico |
| ES2309400T3 (es) * | 2002-12-13 | 2008-12-16 | Smithkline Beecham Corporation | Compuestos de pirrolidina y azetidina como antagonistas de ccr5. |
| TW200524868A (en) | 2003-07-31 | 2005-08-01 | Zeria Pharm Co Ltd | Benzylamine derivatives |
| JPWO2005037269A1 (ja) * | 2003-10-21 | 2006-12-28 | 住友製薬株式会社 | 新規ピペリジン誘導体 |
| GB0412865D0 (en) * | 2004-06-09 | 2004-07-14 | Glaxo Group Ltd | Chemical compounds |
| WO2006020049A2 (en) | 2004-07-15 | 2006-02-23 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| US7745427B2 (en) * | 2004-10-22 | 2010-06-29 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| CA2601709C (en) | 2005-03-22 | 2017-02-14 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids |
| WO2006123182A2 (en) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones for treatment of cancer |
| CA2615403C (en) | 2005-07-15 | 2015-06-16 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| WO2007011878A2 (en) | 2005-07-19 | 2007-01-25 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists |
| BRPI0616463A2 (pt) | 2005-09-29 | 2011-06-21 | Merck & Co Inc | composto, composição farmacêutica, e, uso de um composto |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| CN101190330A (zh) | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
| EP2336120B1 (en) | 2007-01-10 | 2014-07-16 | MSD Italia S.r.l. | Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| JP2010516734A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物 |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体 |
| AU2009222122A1 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| WO2010132487A1 (en) | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
| WO2010132442A1 (en) | 2009-05-12 | 2010-11-18 | Albany Molecular Reserch, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
| US9034899B2 (en) | 2009-05-12 | 2015-05-19 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| BR112012008849A2 (pt) | 2009-10-14 | 2015-09-22 | Schering Corp | composto, composição farmacêutica, e, uso de um composto |
| EP2563127A4 (en) | 2010-04-27 | 2013-11-06 | Merck Sharp & Dohme | PROLYLCARBOXYPEPTIDASE INHIBITORS |
| EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| RU2623209C9 (ru) | 2010-07-01 | 2018-01-22 | Азеван Фармасьютикалз, Инк. | Способы лечения посттравматического стрессового расстройства |
| AU2011285909B2 (en) | 2010-08-02 | 2016-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| US9029341B2 (en) | 2010-08-17 | 2015-05-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| EP2900241B1 (en) | 2012-09-28 | 2018-08-08 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| ES2651347T3 (es) | 2012-11-28 | 2018-01-25 | Merck Sharp & Dohme Corp. | Composiciones y métodos para el tratamiento del cáncer |
| CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| EP2951180B1 (en) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| FI3122743T3 (fi) | 2014-03-28 | 2023-03-02 | Azevan Pharmaceuticals Inc | Koostumuksia ja menetelmiä hermostoa rappeuttavien sairauksien hoitamiseksi |
| CN107849044B (zh) * | 2015-07-03 | 2021-06-25 | 豪夫迈·罗氏有限公司 | 作为ddr1抑制剂的三氮杂-螺癸酮类化合物 |
| WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| BR112020005107A2 (pt) | 2017-09-15 | 2020-11-03 | Azevan Pharmaceuticals, Inc. | composições e métodos para o tratamento de lesão cerebral |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US12173026B2 (en) | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99320A (en) * | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical compositions containing them |
| FR2676055B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
-
1994
- 1994-04-22 WO PCT/US1994/004498 patent/WO1994026735A1/en not_active Ceased
- 1994-04-22 HU HU9503153A patent/HU224496B1/hu not_active IP Right Cessation
- 1994-04-22 AU AU69426/94A patent/AU678023B2/en not_active Ceased
- 1994-04-22 NZ NZ267209A patent/NZ267209A/en unknown
- 1994-04-22 AT AT94917898T patent/ATE158580T1/de not_active IP Right Cessation
- 1994-04-22 DK DK94917898.2T patent/DK0696280T3/da active
- 1994-04-22 CA CA002160462A patent/CA2160462C/en not_active Expired - Fee Related
- 1994-04-22 ES ES94917898T patent/ES2110761T3/es not_active Expired - Lifetime
- 1994-04-22 EP EP94917898A patent/EP0696280B1/en not_active Expired - Lifetime
- 1994-04-22 DE DE69405862T patent/DE69405862T2/de not_active Expired - Lifetime
- 1994-04-22 CN CN94192362A patent/CN1081635C/zh not_active Expired - Fee Related
- 1994-04-22 JP JP52545394A patent/JP3424174B2/ja not_active Expired - Fee Related
- 1994-04-26 TW TW083103768A patent/TW281675B/zh active
- 1994-05-02 IL IL10949694A patent/IL109496A/xx not_active IP Right Cessation
- 1994-05-06 MX MX9403386A patent/MX9403386A/es unknown
-
1995
- 1995-11-02 FI FI955258A patent/FI113047B/fi not_active IP Right Cessation
- 1995-11-03 NO NO954400A patent/NO309144B1/no not_active IP Right Cessation
-
1997
- 1997-11-26 GR GR970403124T patent/GR3025475T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU678023B2 (en) | 1997-05-15 |
| MX9403386A (es) | 1995-01-31 |
| EP0696280B1 (en) | 1997-09-24 |
| CA2160462C (en) | 1998-12-15 |
| JPH09500361A (ja) | 1997-01-14 |
| CN1124961A (zh) | 1996-06-19 |
| DK0696280T3 (da) | 1998-01-12 |
| NZ267209A (en) | 1997-09-22 |
| NO954400L (no) | 1996-01-08 |
| NO309144B1 (no) | 2000-12-18 |
| HUT74085A (en) | 1996-11-28 |
| DE69405862T2 (de) | 1998-01-15 |
| NO954400D0 (no) | 1995-11-03 |
| ATE158580T1 (de) | 1997-10-15 |
| JP3424174B2 (ja) | 2003-07-07 |
| CA2160462A1 (en) | 1994-11-24 |
| IL109496A0 (en) | 1994-08-26 |
| HU224496B1 (hu) | 2005-10-28 |
| AU6942694A (en) | 1994-12-12 |
| FI955258L (fi) | 1995-11-30 |
| DE69405862D1 (de) | 1997-10-30 |
| GR3025475T3 (en) | 1998-02-27 |
| CN1081635C (zh) | 2002-03-27 |
| HU9503153D0 (en) | 1996-01-29 |
| ES2110761T3 (es) | 1998-02-16 |
| WO1994026735A1 (en) | 1994-11-24 |
| IL109496A (en) | 2000-07-26 |
| FI113047B (fi) | 2004-02-27 |
| EP0696280A1 (en) | 1996-02-14 |
| FI955258A0 (fi) | 1995-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW281675B (enExample) | ||
| CA2239174A1 (en) | Novel compounds with analgesic effect | |
| EP1607387A3 (en) | 3,4,4-trisubstituted piperidine derivatives and their use as opioid antagonists | |
| ES2160949T3 (es) | Derivados de fenilen-sulfonamida sustituidos en meta. | |
| BR9917080A (pt) | Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica | |
| MD1233C2 (ro) | Derivaţi de eritromicină, procedeu de preparare a lor şi compoziţie farmaceutică pe baza acestora | |
| CA2217006A1 (en) | Novel substituted piperazine derivatives having tachykinin receptor antagonists activity | |
| MX9803954A (es) | Derivados de aminoacidos, composiciones farmaceuticas que contienen estos compuestos y procesos para prepararlos. | |
| UA34428C2 (uk) | Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки | |
| EP0680328A1 (en) | KETOCONAZOLE COMPOSITIONS FOR LOCAL USE. | |
| DE69631609D1 (en) | Tricyclische erythromycinderivate | |
| WO1999026932A8 (en) | By amidino group substituted heterocyclic derivatives and their use as anticoagulants | |
| AU1442297A (en) | Piperidone tachykinin antagonists | |
| MY120550A (en) | Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions. | |
| MX9708394A (es) | Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion. | |
| MY133169A (en) | Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect | |
| CA2263846A1 (en) | Novel pyranoside derivatives | |
| AU581855B2 (en) | 1-(4'-alkylsulphonylphenyl)-2-amino-1, 3-propanediol n-substituted derivatives | |
| GEP20002271B (en) | Bicyclic Tachykinins Antagonists, Pharmaceutical Composition on Its Basis and Their Use | |
| RU95109891A (ru) | 19,11-перекрытые мостиками 4-эстрены, способ их получения, содержащая их фармацевтическая композиция и промежуточные соединения для их получения | |
| AU3145484A (en) | 1-(4'-alkylthiophenyl)-2-amino-1, 3-propanediol N-substituted derivatives | |
| AU576914B2 (en) | 5-cyanopyridine-2-diazohydroxide, basic salts thereof | |
| WO1995022544A3 (de) | Substituierte 1,3,8-triaza-spiro(4,5)-decan-4-on-derivate als vorstufen zur herstellung von pharmazeutika | |
| MX9703610A (es) | Nuevas (5,6)-heteroaril condensado-pirimidin-4-onas 2,3 disustituidas. | |
| MX9708021A (es) | Fenilamidinas sustituidas, medicamentos que contienen estos compuestos y procedimiento para su preparacion. |